Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POTENT: Postoperative S-1 plus endocrine therapy in ER-positive, HER2-negative breast cancer
jRCTs051180057Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tegafur in breast cancer (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Invasive disease-free survival. Started Feb 2012; status: completed.
02
Drugs
tegafur
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs051180057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180057.